A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

for the 1404-0043 Trial Investigators

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

BACKGROUND: Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction-associated steatohepatitis (MASH). The efficacy and safety of survodutide (a dual agonist of glucagon receptor and GLP-1 receptor) in persons with MASH and liver fibrosis are unclear.

METHODS: In this 48-week, phase 2 trial, we randomly assigned adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of survodutide at a dose of 2.4, 4.8, or 6.0 mg or placebo. The trial had two phases: a 24-week rapid-dose-escalation phase, followed by a 24-week maintenance phase. The primary end point was histologic improvement (reduction) in MASH with no worsening of fibrosis. Secondary end points included a decrease in liver fat content by at least 30% and biopsy-assessed improvement (reduction) in fibrosis by at least one stage.

RESULTS: A total of 293 randomly assigned participants received at least one dose of survodutide or placebo. Improvement in MASH with no worsening of fibrosis occurred in 47% of the participants in the survodutide 2.4-mg group, 62% of those in the 4.8-mg group, and 43% of those in the 6.0-mg group, as compared with 14% of those in the placebo group (P<0.001 for the quadratic dose-response curve as best-fitting model). A decrease in liver fat content by at least 30% occurred in 63% of the participants in the survodutide 2.4-mg group, 67% of those in the 4.8-mg group, 57% of those in the 6.0-mg group, and 14% of those in the placebo group; improvement in fibrosis by at least one stage occurred in 34%, 36%, 34%, and 22%, respectively. Adverse events that were more frequent with survodutide than with placebo included nausea (66% vs. 23%), diarrhea (49% vs. 23%), and vomiting (41% vs. 4%); serious adverse events occurred in 8% with survodutide and 7% with placebo.

CONCLUSIONS: Survodutide was superior to placebo with respect to improvement in MASH without worsening of fibrosis, warranting further investigation in phase 3 trials. (Funded by Boehringer Ingelheim; 1404-0043 ClinicalTrials.gov number, NCT04771273; EudraCT number, 2020-002723-11.).

Original languageEnglish (US)
Pages (from-to)311-319
Number of pages9
JournalNew England Journal of Medicine
Volume391
Issue number4
Early online dateJun 7 2024
DOIs
StatePublished - Jul 25 2024

Keywords

  • Humans
  • Female
  • Male
  • Liver Cirrhosis/drug therapy
  • Middle Aged
  • Double-Blind Method
  • Adult
  • Glucagon-Like Peptide-1 Receptor/agonists
  • Injections, Subcutaneous/adverse effects
  • Fatty Liver/drug therapy
  • Liver/pathology
  • Receptors, Glucagon/agonists
  • Dose-Response Relationship, Drug
  • Aged

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis'. Together they form a unique fingerprint.

Cite this